Dyne Therapeutics (DYN) Jefferies 2024 Global Healthcare Conference summary

Key data and program updates

• Recent data for DMD and DM1 programs was presented earlier than planned due to compelling results, showing meaningful biomarker and functional improvements in both indications.

• Biomarker data, including splicing index for DM1, was shared with the FDA, which confirmed the pathway for accelerated approval remains open.

• Dose escalation in ongoing trials is yielding consistent, dose-dependent improvements in splicing and functional outcomes, with no evidence of a plateau at higher doses.

• Durability of response is observed, with continued improvement in splicing and functional measures over time, including up to 11 months in lower dose cohorts.

• Both DMD and DM1 programs are supported by a strong scientific rationale, leveraging targeted payloads and unique antibody fragments to enhance delivery and minimize side effects.

Regulatory and strategic outlook

• Regulatory discussions are a priority, with the aim to clarify the registration path and leverage multiple potential endpoints for accelerated or full approval.

• The FDA has been positive about the surrogate endpoint approach for DM1, and breakthrough designation is under consideration for both programs.

• The company is maintaining flexibility in endpoint selection, with options to pursue splicing, vHOT, or other functional measures for approval.

• Additional cash was raised to support both programs through the second half of 2026, ensuring sufficient runway for registrational trials.

• Leadership transition was timed to support the shift from clinical development to commercialization, reflecting the company's evolving focus.

Safety and competitive positioning

• No persistent anemia or neutralizing antibodies have been observed, attributed to the specific design of the antibody fragment used in the platform.

• Two cases of pulmonary embolism were not linked to the therapy, with participants remaining in the study and no consistent safety signals observed.

• DMD program data shows favorable safety and efficacy, with significant increases in dystrophin and stable or improving functional outcomes compared to placebo.

• The platform's ability to deliver payloads effectively to target tissues and potentially across the blood-brain barrier is seen as a differentiator.

• The breadth of benefit across multiple functional and quality-of-life measures is highlighted as a competitive advantage.